Contemporary Medical Management of Peripheral Artery Disease.

Circulation Research
Marc P BonacaMark A Creager

Abstract

Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. Modifiable risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity, and physical inactivity, along with underlying genetic factors contribute to lower extremity atherosclerosis. Patients with PAD often have coexistent coronary or cerebrovascular disease, and increased likelihood of major adverse cardiovascular events, including myocardial infarction, stroke and cardiovascular death. Patients with PAD often have reduced walking capacity and are at risk of acute and chronic critical limb ischemia leading to major adverse limb events, such as peripheral revascularization or amputation. The presence of polyvascular disease identifies the highest risk patient group for major adverse cardiovascular events, and patients with prior critical limb ischemia, prior lower extremity revascularization, or amputation have a heightened risk of major adverse limb events. Medical therapies have demonstrated efficacy in reducing the risk of major adverse cardiovascular events and major adverse limb events, and improving function in patients with PAD by modulating key disease determining pathways including inflammation, vascular dysf...Continue Reading

References

Nov 7, 2000·The American Journal of Medicine·D L DawsonD E Strandness
May 7, 2002·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·E P L TurtonD J A Scott
Nov 16, 2002·BMJ : British Medical Journal·Tom MeadeJackie Cooper
Dec 13, 2002·The New England Journal of Medicine·Kerry J StewartAlan T Hirsch
May 4, 2004·European Heart Journal·Martin SchillingerErich Minar
Mar 7, 2006·Journal of the American College of Cardiology·Jay GiriLu Tian
Mar 15, 2006·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHARISMA Investigators
Mar 22, 2007·JAMA : the Journal of the American Medical Association·Ph Gabriel StegUNKNOWN REACH Registry Investigators
May 15, 2007·Journal of the American College of Cardiology·Deepak L BhattUNKNOWN CHARISMA Investigators
Jul 20, 2007·The New England Journal of Medicine·UNKNOWN Warfarin Antiplatelet Vascular Evaluation Trial InvestigatorsGilbert Gosselin
Mar 6, 2008·Vascular and Endovascular Surgery·Andrew Hr StewartPeter M Lamont
Mar 29, 2008·Vascular Medicine·Mark A CreagerWilliam R Hiatt
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Jan 13, 2009·European Heart Journal·Patrice P CacoubUNKNOWN CHARISMA Investigators
Aug 8, 2009·Journal of the American College of Cardiology·Justin D AndersonChristopher M Kramer
Mar 4, 2010·JAMA : the Journal of the American Medical Association·F Gerald R FowkesUNKNOWN Aspirin for Asymptomatic Atherosclerosis Trialists
Apr 23, 2010·The Canadian Journal of Cardiology·Joseph A Vita, Naomi M Hamburg
Dec 15, 2010·Journal of the American College of Cardiology·Deborah HennrikusAlan T Hirsch
Apr 30, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Laura A WheatDaniel J Conklin
Nov 15, 2011·The New England Journal of Medicine·Jessica L MegaUNKNOWN ATLAS ACS 2–TIMI 51 Investigators
Nov 17, 2011·The New England Journal of Medicine·William E BodenWilliam Weintraub
Mar 27, 2012·The New England Journal of Medicine·David A MorrowUNKNOWN TRA 2P–TIMI 50 Steering Committee and Investigators

❮ Previous
Next ❯

Citations

Jun 11, 2021·Circulation Research·Nicholas J Leeper, Naomi M Hamburg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

Cardiovascular & Hematological Disorders Drug Targets
Jayanta R Das, Robert T Eberhardt
Current Drug Targets. Cardiovascular & Haematological Disorders
Robert T Eberhardt, Jay D Coffman
Journal of the National Medical Association
Debabrata Mukherjee, Leslie Cho
© 2021 Meta ULC. All rights reserved